IASLC WCLC 2019: Pembrolizumab Monotherapy Continues to Show Benefit for Non-Small Cell Lung Cancer
Three-year update of KEYNOTE-024 demonstrates favorable safety and efficacy outcomes, compared with chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.